相似文献
1
Expanding the Toolbox of Biomedical HIV Prevention Options Through Innovative Design.
Pharmaceutics. 2025 Jun 5;17(6):742. doi: 10.3390/pharmaceutics17060742.
2
Population-based biomedical sexually transmitted infection control interventions for reducing HIV infection.
Cochrane Database Syst Rev. 2011 Mar 16(3):CD001220. doi: 10.1002/14651858.CD001220.pub3.
3
Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men.
Cochrane Database Syst Rev. 2008 Jul 16(3):CD001230. doi: 10.1002/14651858.CD001230.pub2.
4
Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children.
Cochrane Database Syst Rev. 2010 Nov 10;2010(11):CD003940. doi: 10.1002/14651858.CD003940.pub3.
5
Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure.
Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD002835. doi: 10.1002/14651858.CD002835.pub3.
6
Research designs to generate evidence of HIV post-exposure prophylaxis effectiveness for new long-acting agents.
J Int AIDS Soc. 2025 Jun;28 Suppl 1(Suppl 1):e26475. doi: 10.1002/jia2.26475.
7
How to Implement Digital Clinical Consultations in UK Maternity Care: the ARM@DA Realist Review.
Health Soc Care Deliv Res. 2025 May 21:1-77. doi: 10.3310/WQFV7425.
8
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Cochrane Database Syst Rev. 2011 Jul 6(7):CD003510. doi: 10.1002/14651858.CD003510.pub3.
9
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Cochrane Database Syst Rev. 2007 Jan 24(1):CD003510. doi: 10.1002/14651858.CD003510.pub2.
10
Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.
Health Technol Assess. 2007 Mar;11(9):1-171, iii-iv. doi: 10.3310/hta11090.
本文引用的文献
1
Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial.
Lancet HIV. 2023 Dec;10(12):e779-e789. doi: 10.1016/S2352-3018(23)00227-8. Epub 2023 Oct 25.
2
Long-acting injectable multipurpose prevention technology for prevention of HIV and unplanned pregnancy.
J Control Release. 2023 Nov;363:606-620. doi: 10.1016/j.jconrel.2023.10.006. Epub 2023 Oct 12.
3
Perspectives on long-acting formulations of pre-exposure prophylaxis (PrEP) among men who have sex with men who are non-adherent to daily oral PrEP in the United States.
BMC Public Health. 2023 Aug 28;23(1):1643. doi: 10.1186/s12889-023-16382-4.
4
Ultra-long-acting in-situ forming implants with cabotegravir protect female macaques against rectal SHIV infection.
Nat Commun. 2023 Feb 9;14(1):708. doi: 10.1038/s41467-023-36330-5.
5
Preferences for pre-exposure prophylaxis for HIV: A systematic review of discrete choice experiments.
EClinicalMedicine. 2022 Jul 9;51:101507. doi: 10.1016/j.eclinm.2022.101507. eCollection 2022 Sep.
6
Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study.
Lancet HIV. 2022 Aug;9(8):e554-e562. doi: 10.1016/S2352-3018(22)00133-3. Epub 2022 Jun 27.
7
Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis.
Lancet HIV. 2022 Apr;9(4):e254-e268. doi: 10.1016/S2352-3018(22)00030-3.
8
Vaginal ring acceptability and related preferences among women in low- and middle-income countries: A systematic review and narrative synthesis.
PLoS One. 2019 Nov 8;14(11):e0224898. doi: 10.1371/journal.pone.0224898. eCollection 2019.
9
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.
N Engl J Med. 2015 Dec 3;373(23):2237-46. doi: 10.1056/NEJMoa1506273. Epub 2015 Dec 1.
Zotero 插件